IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) and NeuroPace (NASDAQ:NPCE – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.
Earnings and Valuation
This table compares IDEXX Laboratories and NeuroPace”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IDEXX Laboratories | $4.30 billion | 12.30 | $1.06 billion | $14.22 | 47.26 |
| NeuroPace | $99.99 million | 4.23 | -$21.47 million | ($0.57) | -21.60 |
IDEXX Laboratories has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares IDEXX Laboratories and NeuroPace’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IDEXX Laboratories | 25.36% | 71.04% | 33.99% |
| NeuroPace | -19.34% | -105.64% | -16.51% |
Analyst Ratings
This is a breakdown of recent recommendations for IDEXX Laboratories and NeuroPace, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IDEXX Laboratories | 0 | 6 | 7 | 0 | 2.54 |
| NeuroPace | 1 | 1 | 7 | 1 | 2.80 |
IDEXX Laboratories currently has a consensus target price of $719.55, suggesting a potential upside of 7.07%. NeuroPace has a consensus target price of $19.33, suggesting a potential upside of 57.05%. Given NeuroPace’s stronger consensus rating and higher possible upside, analysts plainly believe NeuroPace is more favorable than IDEXX Laboratories.
Insider and Institutional Ownership
87.8% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 0.8% of IDEXX Laboratories shares are held by company insiders. Comparatively, 19.2% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
IDEXX Laboratories has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, NeuroPace has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500.
Summary
IDEXX Laboratories beats NeuroPace on 9 of the 14 factors compared between the two stocks.
About IDEXX Laboratories
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
About NeuroPace
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
